GO:0036019 endolysosome: Components, Assembly and Research Methods

The endolysosome (GO:0036019) is defined in QuickGO as a transient hybrid organelle formed by fusion of a late endosome with a lysosome, and in which active degradation takes place. This organelle represents a critical convergence point of the endocytic and autophagic pathways, where cargo delivered from the plasma membrane, Golgi and autophagosomes meets the acidic hydrolase-rich environment required for macromolecule breakdown. Because of its transient nature, the endolysosome is both a degradation station and a signaling platform that coordinates nutrient availability with cellular metabolism. For researchers, GO:0036019 matters because defects in endolysosome formation, fusion or function are increasingly linked to human disease. Impaired endolysosome and autophagy function has been reported in Alzheimer disease, where altered clearance contributes to protein aggregation and neuronal toxicity. In Huntington disease, lowering mutant huntingtin levels through autophagy-endolysosome pathways is a therapeutic strategy under investigation. Endolysosome function also influences iron metabolism and brain carcinogenesis, expanding its relevance beyond classical lysosomal storage disorders. Recent work has revealed unexpected roles for the endolysosome in secretion and development. Inhibition of endolysosome fusion increases exosome secretion, indicating that this organelle controls extracellular vesicle release. In mouse oocytes, degradative super-organelles related to endolysosomes sequester aggregated proteins, highlighting specialized functions in development. Metabolic control from the endolysosome, mediated by lysosome-resident amino acid transporters, opens novel therapeutic possibilities. These findings make GO:0036019 a high-value target for functional genomics and CRISPR-based modeling.

In our own words, the endolysosome is a short-lived hybrid organelle created when a late endosome fuses with a lysosome. During its lifetime, it carries out active degradation of proteins, lipids and other macromolecules using lysosomal hydrolases in an acidic lumen. Because it is transient, the endolysosome is best understood as a dynamic intermediate in the endolysosomal maturation pathway rather than a stable compartment.

The endolysosome is important because it sits at the crossroads of degradation, nutrient sensing and secretion, and its dysfunction is mechanistically linked to major human diseases. Endolysosome and autophagy dysfunction in Alzheimer disease impairs clearance of aggregated proteins, contributing to neuronal toxicity. In Huntington disease, modulating autophagy-endolysosome pathways can lower mutant huntingtin levels and toxicity. Endolysosome function also affects iron metabolism and brain carcinogenesis, suggesting roles in metal homeostasis and tumor biology. Beyond disease, the endolysosome controls exosome secretion, a key mode of intercellular communication, and supports metabolic control through lysosome-resident amino acid transporters. Understanding GO:0036019 is therefore essential for researchers in neurodegeneration, cancer metabolism and extracellular vesicle biology.

The following genes and proteins are experimentally implicated in endolysosome biology, fusion, homeostasis and related disease pathways.

Endolysosome formation and function are regulated at multiple levels. Small GTPases such as Arf1 and Rab4 control recruitment of effectors like LRBA to endosomes, and this Arf1-dependent LRBA recruitment is required for endolysosome homeostasis. Fusion between late endosomes and lysosomes is a regulated step; inhibiting this fusion increases exosome secretion, indicating that fusion is actively controlled. Nutrient status influences endolysosome behavior through lysosome-resident amino acid transporters that mediate metabolic control from the endolysosome. In disease contexts, autophagy-endolysosome pathway activity is modulated in Huntington disease, where lowering mutant huntingtin levels depends on this pathway, and endolysosome and autophagy dysfunction is observed in Alzheimer disease. Iron metabolism also intersects with endolysosome regulation, linking metal homeostasis to organelle function.

Endolysosome and autophagy dysfunction has been reported in Alzheimer disease, where impaired clearance of aggregated proteins contributes to neuronal toxicity. Amyloid precursor protein processing and tau aggregation are both connected to endolysosomal compartments, making GO:0036019 a mechanistic node in disease progression. Therapeutic strategies that restore endolysosome function are therefore of interest in neurodegeneration research.

In Huntington disease, lowering mutant huntingtin levels and toxicity depends on autophagy-endolysosome pathways. Modulating these pathways is a proposed therapeutic approach, and the endolysosome is a key intermediate where autophagic cargo is degraded. This links GO:0036019 directly to polyglutamine disease biology.

Endolysosome function plays a role in iron metabolism and brain carcinogenesis, suggesting that the organelle influences metal homeostasis and tumor development in the brain. This expands the disease relevance of GO:0036019 beyond neurodegeneration into cancer biology. Researchers can use endolysosome-focused models to dissect these links.

Inhibition of endolysosome fusion increases exosome secretion, connecting GO:0036019 to extracellular vesicle release. Because exosomes carry disease-associated cargo, altered endolysosome function may change how pathological signals spread between cells. This has implications for cancer, neurodegeneration and biomarker research.

Fluorescence microscopy with lysosomal and late endosomal markers allows visualization of endolysosome formation and fusion events. Tagged knock-in of proteins such as LRBA enables tracking of recruitment to Rab4 endosomes, which is required for endolysosome homeostasis. Live-cell imaging can capture the transient nature of GO:0036019 and quantify fusion frequency.

Proteomic analysis of isolated endolysosomal fractions can identify components and cargo of the hybrid organelle. This approach helps define the molecular composition of GO:0036019 and its changes under disease conditions. Comparative proteomics between wild-type and CRISPR knockout cells can reveal gene-specific effects on endolysosome composition.

Degradation assays measure the capacity of endolysosomes to break down cargo, reflecting the active degradation that defines GO:0036019. Exosome secretion assays can test whether inhibiting endolysosome fusion increases exosome release. Combining these assays with genetic perturbation provides causal evidence for gene function.

RNA-seq of cells with endolysosome-related gene perturbations can reveal downstream transcriptional programs, including autophagy and lysosomal gene networks. Pathway enrichment can connect GO:0036019 to disease-relevant processes such as neurodegeneration and metabolism. These datasets support hypothesis generation for CRISPR follow-up studies.

Researchers studying endolysosome-related genes often need to determine whether a candidate gene is causally involved in organelle formation, degradation or disease-associated dysfunction. Establishing causality requires precise genetic models that can remove, modify or tag the gene of interest in relevant cell types. EDITGENE provides end-to-end CRISPR services tailored to GO:0036019 research, from knockout validation to knock-in reporter lines and library screening.

GO:0036019 endolysosome is a transient hybrid organelle formed by fusion of a late endosome with a lysosome, where active degradation takes place. Its functions extend to metabolic signaling, exosome secretion and disease-relevant clearance pathways, with documented roles in Alzheimer disease, Huntington disease and brain carcinogenesis. Studying endolysosome biology requires precise genetic models, and CRISPR knockout, point mutation, knock-in and overexpression approaches provide the causal evidence needed to move from correlation to mechanism.